With close ties to University of Pennsylvania - facilities used and personnel identified on several issued patents - published literature indicates Five Eleven Pharma to be "self-funding" two Phase I clinical trials to determine human dosimetry and pharmacokinetics in cancer patients using. Preliminary data from these trials it is indicated has shown a good safety profile, favorable dosimetry and accumulation of a critical PSMA-expressing tissue and prostate cancer lesions. Overall, however, the firm has a limited digital footprint
